E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10037153 |
E.1.2 | Term | Psoriasis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of the study is to investigate whether treatment with HuMax-Inflam induces regression or reduces progression of inflammatory, progressive psoriasis in comparison with isotonic saline solution. |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Diagnosed with inflammatory, progressive psoriasis vulgaris 2) Man or woman ≥18 years of age 3) Development of psoriasis on tape-stripped skin within 3 weeks (Koebner-positive patients) 4) Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study-related activity is carried out
|
|
E.4 | Principal exclusion criteria |
1) A diagnosis of pustular psoriasis 2) Koebner-negative patients 3) Patients previously treated with HuMax-Inflam 4) Treatment with systemic antipsoriatic drugs: etretinate, methotrexate, salazopyrine or cyclosporine ≤4 weeks prior to treatment start 5) Local treatment with antipsoriatic drugs and UV radiation within 20 cm of the injection area ≤2 weeks before treatment start 6) Primary or secondary immunodeficiency 7) Active autoimmune disease requiring treatment (in addition to psoriasis vulgaris) 8) Psoriatic rheumatism requiring systemic treatment except for Non-Steroid Antiinflammatoryr Drugs (NSAIDs) 9) Previous or current malignant disease except: a Cervix carcinoma Stage 1B or lower b Noninvasive basal cell carcinoma c Malignant melanoma with a complete response duration of more than 10 years d Other cancer diagnoses with a complete response duration of more than 5 years 10) Chronic or active infections such as (but not limited to) chronic kidney infection, chronic pulmonary infection with bronchial ectasia, rhinitis, and tuberculosis 11) Clinically significant heart disease including unstable angina, acute myocardial infarction within 6 months of Visit 1, heart failure, and arrhythmias requiring treatment except for extrasystoles and minor conductivity anomalies 12) Significant treatment requiring disease; disease conditions of (but not limited to) the kidneys, liver, hematological conditions, gastrointestinal tract, endocrine system, lungs, nervous system – including cerebral conditions, or mental disease 13) Previous significant cerebrovascular disease 14) Known or suspected HIV seropositive status 15) Known or suspected hepatitis B or hepatitis C 16) Laboratory values at screening: Hemoglobin <5.3 mmol/L Neutrophil granulocytes < 1.5 x109/L Thrombocytes <100 x109/L. S- ALT >2 times the upper normal limit S- ALP >2 times the upper normal limit S-creatinine >133 µmol/L 17) Known or suspected sensitivity to the ingredients in the investigational product 18) Patients who have been treated with any non-marketed drug within 4 weeks of Visit 1 19) Concurrent participation in any other clinical trial 20) Patients who are known to be or suspected of being incapable of complying with the study protocol (for example, due to alcoholism, substance abuse or psychiatric illness) 21) Women who breast feed or women with a positive pregnancy test at Visit 1 22) Women of reproductive potential who are not willing to use a contraceptive, defined as oral contraceptive or a coil during the study or 3 months after the final HuMax-Inflam injection
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The Investigator’s overall assessment of disease activity in the treated areas. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.1.7.1 | Other trial design description |
Subjects are their own control. |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | |